Loading...

Home
ETF
ABUS

ABUS

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

ABUS News

Arbutus Biopharma Shares Rise 10% After Patent Ruling

Feb 02 2026seekingalpha

Health Care Stocks Decline as NYSE Health Care Index Eases 0.5%

Jan 16 2026Yahoo Finance

Arbutus Biopharma (ABUS) Patent Revocation Leads to 18% Stock Crash

Jan 16 2026stocktwits

Arbutus Biopharma (ABUS) Patent Revocation Leads to 14% Pre-Market Drop

Jan 16 2026seekingalpha

Chardan Capital Reaffirms Buy Rating for Arbutus Biopharma with $5 Price Target Intact

Nov 14 2025Benzinga

Arbutus (ABUS) Q2 Revenue Surges 529%

Aug 06 2025NASDAQ.COM

Arbutus Biopharma Corp. Q2 Earnings Summary

Aug 06 2025NASDAQ.COM

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Jun 25 2025Newsfilter

Arbutus Biopharma GAAP EPS of -$0.13 misses by $0.03, revenue of $1.76M beats by $0.17M

May 14 2025SeekingAlpha

Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

May 07 2025Newsfilter

Arbutus Biopharma Reports Positive Phase 2a Results for Imdusiran in Combination with VTP-300 and Low Dose Nivolumab in Chronic Hepatitis B Patients at EASL 2025

May 07 2025NASDAQ.COM

Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Apr 23 2025Newsfilter

Arbutus Biopharma Announces Acceptance of Five Abstracts for Presentation at EASL Congress 2025

Apr 01 2025NASDAQ.COM

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

Mar 03 2025Newsfilter

Biotech Alert: Searches spiking for these stocks today

Feb 28 2025Business Insider

Arbutus Biopharma Appoints Lindsay Androski To Replace Michael McElhaugh As CEO

Feb 25 2025NASDAQ.COM